MedTrace Logo

Phendimetrazine and Cocaine

NCT02233647 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2017-09-27

Study results available
· View outcomes & findings →

Summary

This study will determine the safety and tolerability of phendimetrazine (Bontril®) as a pharmacotherapy for cocaine use disorder. A rigorous, inpatient human laboratory study will be conducted in which the subjective and physiological effects of cocaine are evaluated during maintenance on placebo and phendimetrazine.

Conditions

  • Cocaine Use Disorder

Interventions

DRUG

Cocaine

The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and phendimetrazine.

DRUG

Placebo

The pharmacodynamic effects of placebo will be determined during maintenance on placebo and phendimetrazine.

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • William Stoops

    lead OTHER

Principal Investigators

  • William W Stoops, Ph.D. · University of Kentucky

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02233647 on ClinicalTrials.gov